Delivery Order SPE2DB20D1100-SPE2DB25FD9C7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- On August 5, 2025, the Defense Logistics Agency awarded a delivery order valued at $48,364.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections. This firm fixed-price delivery order, which is not set-aside designated, represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The products will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $12,307.65. This is a firm fixed price delivery order with no set-aside designation, issued competitively to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $12,356.56 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price contract, which received no set-aside designation, leverages AmerisourceBergen's position as a major pharmaceutical distributor supporting federal medical procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $27,256.30 on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $1,709.46. This firm fixed-price delivery order, which is expected to be completed by August 1, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The award is not set-aside and was competitively awarded, with the place of performance...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD9C7Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injections, with a contract ceiling value of $1,709.46. This is a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as the comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor in the federal medical procurement supply chain, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio of federal contracts demonstrates its capability to meet diverse medical supply requirements, ranging from specialty medications and brand-name pharmaceuticals to generic drugs, vaccines, and medical devices across multiple therapeutic domains. The SPE2DX IDC enables the company to provide pharmaceutical support globally to military healthcare operations, and the company is positioned to continue serving federal customers as the Defense Logistics Agency plans to establish next-generation Pharmaceutical Prime Vendor Global Program contracts with multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/7/25 |